Ralinepag

Unassigned

New Medicines

Pulmonary hypertension when added to background therapy

Information

New molecular entity
Arena
Arena

Development and Regulatory status

None
Phase II Clinical Trials
Phase III Clinical Trials
Yes

Category

Prostacyclin receptor agonist
The estimated annual incidence of PAH in the UK general population ranges from 0.9 to 7.6 cases per 1,000,000 people and the estimated prevalence of PAH in the UK general population is between 6.6 and 26 per 1,000,000 people. These figures are thought to be underestimates due to misdiagnosis or underdiagnoses of PAH patients [1].
Pulmonary hypertension when added to background therapy
Oral